25-MAY-2024 6:10

MMYEL ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1803-MM, Maintenance, Len vs Len/Dara 1 Y 0 Screening 1420 1247 106 106 67 28 5 08/13/2019 311 119
            1247 106 106 67 28 5      
 
    2 Y 1 Lenalidomide   574 54 46 30 16 2 08/13/2019    
        2 Lenalidomide + Daratumumab   567 56 50 33 14 3      
            1141 110 96 63 30 5      
 
    3 Y 3 Stop vs Continue Treatment   185 92 36 19 6 2 08/13/2019    
            185 92 36 19 6 2      
 
  S2005-WM, Prev. Untreated, I/R +/- Venetoclax 1 Y 1 I+R 62 1 1 1 1 0 0 01/05/2022 66 24
        2 I+R+Venetoclax   1 0 0 0 0 0      
        3 V+R   1 1 1 1 1 1      
            3 2 2 2 1 1      
 
  S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 1 Y 1 VRD-R 510 8 8 7 3 1 0 10/12/2023 175 66
        2 DRD-R   8 8 8 3 1 0      
        3 DRD-DR   8 8 6 3 2 1      
            24 24 21 9 4 1      
 
Yes EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) 0 E Total Registrations   46 22 7 2 0 0 05/27/2021 201 86
            46 22 7 2 0 0      
 
    1 E Total Registrations   35 17 7 2 0 0 05/27/2021    
            35 17 7 2 0 0      
 
    2 E Total Registrations   19 11 6 4 2 1 05/27/2021    
            19 11 6 4 2 1      
 
No EAA173-MYEL, SMM, Rd +/- Daratumumab 0 E Total Registrations   67 18 11 9 4 0 01/08/2020 223 97
            67 18 11 9 4 0      
 
    1 E Total Registrations   30 8 5 4 3 1 01/08/2020    
            30 8 5 4 3 1      
 

25-MAY-2024 6:10

MMYEL Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs
# of
CURR
IRBs
S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 1 Induction 01-Dec-23 72 22
  2 Randomization 01-Dec-23 72 22
  3 Maintenance 01-Dec-23 72 22